OPIOID AGONIST ANTAGONISM – nalbuphine is an excellent option for
titration/reversal of unwanted mu agonist effects such as excess sedation
or prolonged anesthetic recovery and respiratory depression without the
loss of all analgesia,.
OF ADVERSE EFFECTS – nalbuphine is generally free of any adverse
cardiovascular, respiratory, or gastrointestinal adverse effects,,,,,.
PROPERTIES – nalbuphine provides mild analgesia or short duration,,.
– nalbuphine provides minimal sedation as a sole agent in healthy
patients. Sedation may be more consistent in depressed patients. When
combined with the alpha-2 agonist, medetomidine, significant short
duration sedation and enhanced analgesia are predictable even in young,
MAC SPARING EFFECT – nalbuphine has been shown to reduce enflurane
MAC at doses as low as 0.5 mg/kg.
EFFECTS DURING SHOCK – nalbuphine has been shown to improve patient
survivability at doses from 1 to 5 mg/kg.
WHEN DELIVERED ORALLY – oral bioavailability is approximately 5%.